Physician profile
Mitchell Lampert
NPI 1588682678
$2,138.99
in general payments reported to CMS, 2019-2025
27 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $199 · 2021: $151 · 2022: $296 · 2023: $396 · 2024: $406 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $522.26 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $287.44 | 2019-2025 | Veozah, Myrbetriq |
| Atricure, INC. | $143.51 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $129.00 | 2025 | Airsupra |
| Abbott Laboratories | $109.64 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $102.28 | 2023-2025 | |
| Boston Scientific Corporation | $90.82 | 2019-2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $74.48 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $68.52 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $65.03 | 2024-2025 | Gemtesa |
| Saluda Medical Americas, INC. | $53.79 | 2024 | Evoke |
| Medtronic, INC. | $52.33 | 2024 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $50.81 | 2022-2025 | Trelegy Ellipta |
| Smith+Nephew, INC. | $43.82 | 2024 | Or3o Dual Mobility, Real Intelligence |
| Lilly USA, LLC | $41.49 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35.71 | 2022-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $34.28 | 2019-2022 | |
| Abbvie INC. | $34.07 | 2022-2023 | |
| Amarin Pharma, INC. | $28.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.90 | 2019 | |
| Kvk-Tech, INC. | $26.65 | 2019 | |
| Biosense Webster, INC. | $22.77 | 2022 | |
| Genentech USA, INC. | $21.70 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.18 | 2024 | Rexulti |
| Eisai INC. | $20.53 | 2025 | |
| Hologic Sales and Service, LLC | $16.69 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Lampert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.